Trial Profile

Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous-stem-cell-therapy-Regeneration-Biomedical (Primary) ; Autologous-stem-cell-therapy-Regeneration-Biomedical (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Sponsors Regeneration Biomedical

26 Aug 2026 Planned End Date changed from 1 Mar 2029 to 1 Feb 2030.
26 Aug 2026 Planned primary completion date changed from 1 Mar 2028 to 1 Feb 2029.
26 Aug 2026 Planned initiation date changed from 1 Nov 2025 to 1 Oct 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com